[1] Hwang S Y, Danpanichkul P, Agopian V, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment[J]. Clin Mol Hepatol, 2025, 31(Suppl):S228-S254. [2] 刘立友, 吴东洋, 蔡青山, 等. 原发性肝癌组织中层粘连蛋白3、黏着斑激酶蛋白表达及其与患者临床病理特征和预后关系研究[J]. 陕西医学杂志, 2023, 52(9):1259-1263. [3] Zou Y, Shi H, Lin H, et al. The abrogation of GRP78 sensitizes liver cancer cells to lysionotin by enhancing ER stress-mediated pro-apoptotic pathway[J]. Cell Stress Chaperones, 2023, 28(4):409-422. [4] Xie M, Sun M, Ji X, et al. Overexpression of BACH1 mediated by IGF2 facilitates hepatocellular carcinoma growth and metastasis via IGF1R and PTK2[J]. Theranostics, 2022, 12(3):1097-1116. [5] Benson A B, D'Angelica M I, Abbott D E, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565. [6] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. [7] Chan Y T, Zhang C, Wu J, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma[J]. Mol Cancer, 2024, 23(1):189. [8] Lu F, Shah P A, Rao A, et al. Liver cancer-specific serine protease inhibitor kazal is a potentially novel biomarker for the early detection of hepatocellular carcinoma[J]. Clin Transl Gastroenterol, 2020, 11(12):e00271. [9] Shin D W, Moon S H, Kim J H. Diagnosis of cholangiocarcinoma[J]. Diagnostics (Basel), 2023, 13(2):233. [10] Wang Y, Wang J, Liu Y, et al. Multidimensional pan-cancer analysis of HSPA5 and its validation in the prognostic value of bladder cancer[J]. Heliyon, 2024, 10(6):e27184. [11] 高龙, 马海东, 白明圳, 等. GRP78在胆管癌组织中的表达及其与预后的关系[J]. 现代肿瘤医学, 2023, 31(15):2861-2867. [12] Mofed D, Wahba M A, Salem T Z. Genetically engineered hepatitis c virus-like particles (HCV-LPs) tagged with SP94 peptide to acquire selectivity to liver cancer cells via Grp78[J]. Curr Issues Mol Biol, 2022, 44(8):3746-3756. [13] Ajoolabady A, Kaplowitz N, Lebeaupin C, et al. Endoplasmic reticulum stress in liver diseases[J]. Hepatology, 2023, 77(2):619-639. [14] Ishteyaque S, Yadav K S, Verma S, et al. CYP2E1 triggered GRP78/ATF6/CHOP signaling axis inhibit apoptosis and promotes progression of hepatocellular carcinoma[J]. Arch Biochem Biophys, 2023, 745:109701. [15] Cai M N, Chen D M, Xiao L X, et al. COLEC10 induces endoplasmic reticulum stress by occupying GRP78 and inhibits hepatocellular carcinoma[J]. Lab Invest, 2023, 103(7):100130. [16] Noh M H, Kang J M, Miller A A, et al. Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy[J]. Neuro Oncol, 2024, 26(9):1602-1616. [17] Lin J, Rao D, Zhang M, et al. Metabolic reprogramming in the tumor microenvironment of liver cancer[J]. J Hematol Oncol, 2024, 17(1):6. [18] Liu B, Hu Y, Wan L, et al. Proteomics analysis of cancer tissues identifies IGF2R as a potential therapeutic target in laryngeal carcinoma[J]. Front Endocrinol (Lausanne), 2022, 13:1031210. [19] Zhu X Y, Liu W T, Hou X J, et al. CD34+CLDN5+ tumor associated senescent endothelial cells through IGF2-IGF2R signaling increased cholangiocellular phenotype in hepatocellular carcinoma[J]. J Adv Res, 2025,76:511-528. [20] Tian Y, Han W, Fu L, et al. IGF2 is upregulated by its antisense RNA to potentiate pancreatic cancer progression[J]. Funct Integr Genomics, 2023, 23(4):348. |